What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.